Bovine lactoferrin and its tryptic peptides: Antibacterial activity against different species
- Authors: Lizzi A.R.1, Carnicelli V.1, Clarkson M.M.1, Nazzicone C.1, Segatore B.1, Celenza G.1, Aschi M.2, Dolo V.3, Strom R.4, Amicosante G.1
-
Affiliations:
- Department of Biotechnological and Applied Clinical Sciences
- Department of Physical and Chemical Sciences
- Department of Life, Health and Environmental Sciences
- Department of Cellular Biotechnologies and Haematology
- Issue: Vol 52, No 4 (2016)
- Pages: 435-440
- Section: Article
- URL: https://journals.rcsi.science/0003-6838/article/view/151974
- DOI: https://doi.org/10.1134/S0003683816040116
- ID: 151974
Cite item
Abstract
The research of new antimicrobial compounds has an impact on public health and economy of many countries. Given the great problem of bacterial resistance, the study of new molecules that bypass this mechanism is of great importance. Trypsin is an enzyme necessary for gut physiology and the peptides it forms could be of great interest to the pharmaceutical industry. In this study the antibacterial activity of undigested and trypsin-hydrolyzed iron-depleted form of lactoferrin, (apo-bLf) and undigested and diferric bovine lactoferrin (bLf) were evaluated against different bacterial species. Apo-bLf was less susceptible to trypsin hydrolysis compared to the diferric form and its tryptic fragments with molecular weight lower than 5000 Da had greater activity than those obtained from the diferric-bLf. It is plausible that the antimicrobial activity is exerted mainly by the interaction of the N-terminal moiety of the protein with the bacterial cell. The in silico analysis of the interdomain movements, showed that the conformation of the active N-terminal part of apo-bLf is more open than that of the diferric form. The increased accessibility of the N-terminal region seems to be responsible for the antimicrobial activity of the apo-bLf and its tryptic fragments.
Keywords
About the authors
A. R. Lizzi
Department of Biotechnological and Applied Clinical Sciences
Author for correspondence.
Email: arlizzi@cc.univaq.it
Italy, Coppito 2, Via Vetoio, L’Aquila, I-67100
V. Carnicelli
Department of Biotechnological and Applied Clinical Sciences
Email: arlizzi@cc.univaq.it
Italy, Coppito 2, Via Vetoio, L’Aquila, I-67100
M. M. Clarkson
Department of Biotechnological and Applied Clinical Sciences
Email: arlizzi@cc.univaq.it
Italy, Coppito 2, Via Vetoio, L’Aquila, I-67100
C. Nazzicone
Department of Biotechnological and Applied Clinical Sciences
Email: arlizzi@cc.univaq.it
Italy, Coppito 2, Via Vetoio, L’Aquila, I-67100
B. Segatore
Department of Biotechnological and Applied Clinical Sciences
Email: arlizzi@cc.univaq.it
Italy, Coppito 2, Via Vetoio, L’Aquila, I-67100
G. Celenza
Department of Biotechnological and Applied Clinical Sciences
Email: arlizzi@cc.univaq.it
Italy, Coppito 2, Via Vetoio, L’Aquila, I-67100
M. Aschi
Department of Physical and Chemical Sciences
Email: arlizzi@cc.univaq.it
Italy, Coppito 1, Via Vetoio, L’Aquila, I-67100
V. Dolo
Department of Life, Health and Environmental Sciences
Email: arlizzi@cc.univaq.it
Italy, Coppito 2, Via Vetoio, L’Aquila, I-67100
R. Strom
Department of Cellular Biotechnologies and Haematology
Email: arlizzi@cc.univaq.it
Italy, Rome, I-00161
G. Amicosante
Department of Biotechnological and Applied Clinical Sciences
Email: arlizzi@cc.univaq.it
Italy, Coppito 2, Via Vetoio, L’Aquila, I-67100
Supplementary files
